Abstract
mUC is an aggressive disease with limited overall survival. HER2 overexpression is associated with poor prognosis and occurs in a significant number of patients (pts) with mUC. HER2-targeted ADCs represent a promising strategy in mUC, with multiple ongoing clinical trials. We aimed to realize a systematic review of efficacy and toxicity of anti-HER2 ADCs in mUC.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
